COMMUNIQUÉS West-GlobeNewswire

ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
03/02/2026
Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company’s Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company [...]
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
03/02/2026
Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company [...]
Tilray Brands Ignites Championship Sunday: Nationwide Tap Room Events, Big Game Day Deals, and Fan Experiences Announced
03/02/2026
Gear up for game day, Sunday, February 8, 2026, with ultimate fan experiences, beer, wings, whiskey, and more at SweetWater Brewing Co., Montauk Brewing Co., Breckenridge Brewery, Blue Point Brewing Co., 10 Barrel [...]
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
03/02/2026
LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans [...]
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
03/02/2026
OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
03/02/2026
FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
TSC Life Receives FDA Clearance for Pediatric Use with Fluido® Compact System, a Blood & Fluid Warmer, in the U.S. and Canada
03/02/2026
DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- TSC Life , a global medtech company redefining healthcare with high-performance devices for temperature management and endoscopy, announced today that the U.S. Food and Drug [...]
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
03/02/2026
Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
03/02/2026
This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. [...]
62,752 Orion Corporation A shares converted into B shares
03/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 3 FEBRUARY 2026 at 9.00 EET 62,752 Orion Corporation A shares converted into B shares In accordance with [...]
Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine
03/02/2026
First publication of clinical efficacy data for PP353, in development for chronic Low Back Pain Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with [...]
Zelluna promotes Emilie Gauthy to Chief Technology Officer
03/02/2026
Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced the [...]
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones
03/02/2026
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones Lausanne, Switzerland — 03 February 2026 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off- [...]
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment
03/02/2026
February 3, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and [...]
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
03/02/2026
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company [...]
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
03/02/2026
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone ( [...]
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
03/02/2026
Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion. On [...]
Communiqué de presse : Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros
03/02/2026
Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros Paris, 3 février 2026. Le 29 janvier 2026, Sanofi a annoncé son intention d’exécuter un programme de rachat d' [...]
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
03/02/2026
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today [...]

Pages